Ab­b­Vie shells out $440M on two PRVs for la­bel ex­pan­sions of its block­buster Rin­voq

The pri­or­i­ty re­view vouch­er mar­ket can be no­to­ri­ous­ly se­cre­tive, es­pe­cial­ly when com­pa­nies pur­chase PRVs and don’t dis­close where they’re plan­ning to use the ex­pe­dit­ed FDA re­views.

For Ab­b­Vie, that strat­e­gy has been plain and sim­ple so far: ex­pand block­buster Rin­voq’s la­bel as quick­ly as pos­si­ble.

Back in 2015, the Chica­go-based biotech spent an eye-open­ing $350 mil­lion on a PRV from Unit­ed Ther­a­peu­tics — more than any oth­er PRV sold ever — and used it to win ap­proval for Rin­voq as a treat­ment for adults with mod­er­ate­ly to se­vere­ly ac­tive rheuma­toid arthri­tis.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER